Clinical Trial Update: DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs [Phase 3]

View source ↗

Summary

Phase III DETECT III trial completed. It evaluated adding lapatinib to standard therapy in HER2-negative metastatic breast cancer patients with HER2-positive ci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Tykerb) (lapatinib)

Snippet

Sponsor: Prof. Wolfgang Janni | Conditions: HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells | Phase 3 | Status: COMPLETED